Excessive daytime sleepiness linked with higher stroke risk Philippine Star, Philippines - Nov 29, 2008 Patients who reported some dozing had more than twice the risk of both ischemic stroke and all types of stroke, compared with people who reported no dozing, ...
Rationale and Design of CURRENT-OASIS 7 Study Published in ... MarketWatch - Nov 5, 2008 ... patients with recent MI, recent ischemic stroke, or established peripheral artery disease receiving Plavix(R) alone were followed for up to three years. ...
Athersys, Inc. Q3 2008 Earnings Call Transcript Seeking Alpha, NY - Nov 27, 2008 In addition, we have made important progress in key preclinical programs in areas like ischemic stroke and our H3 antagonist program. ...ATHX
Surrogate Consent Crucial to Trial's Success, Researchers Conclude Media Newswire (press release), NY - Nov 11, 2008 Acute ischemic stroke occurs when an artery to the brain is blocked by a blood clot. The trial took slightly less than four years to complete, enrolling 624 ...
Stem Cell Therapeutics Corp. Announces Third Quarter 2008 ... eMediaWorld.com Newswire Press Release Distribution Service (press release), AZ - Nov 26, 2008 ... is designed to demonstrate that the NTx(TM)-265 therapy is both a safe and effective therapy capable of improving recovery after acute ischemic stroke. ...CVE:SSS - TSE:X
Micrus Endovascular Reports First Quarter Financial Results FOXBusiness - 23 minutes ago Hemorrhagic and ischemic stroke are both significant causes of death and disability worldwide. The Micrus product line enables physicians to gain access to ...MEND
Brain scientist?s book a stroke of suffering and genius Worcester Telegram, MA - After a night in the hospital, I suffered a second stroke that paralyzed my left side even further. I could not lift my left arm nor move my left leg. ...
Fish May Boost Memory, Prevent Stroke WebMD - Aug 4, 2008 The lesion is dubbed "silent" if it developed in someone who has not had a recognized stroke or transient ischemic attack (TIA), also called a mini-stroke. ...
NMT Medical Announces Second-Quarter 2008 Financial Results Business Wire (press release), CA - Aug 5, 2008 Our strategy has been to be the first company in the space to provide the required clinical evidence through our pivotal PFO/stroke clinical trial, ...NMTI
Athersys Reports 2008 Second Quarter Results MarketWatch - ... including damage caused by myocardial infarction, bone marrow transplantation/oncology support, ischemic stroke and other indications. ...ATHX
Intensive Lipid Intervention in the Post-ENHANCE Era RedOrbit, TX - Aug 5, 2008 High- dose atorvastatin therapy has produced similar marked benefits in 2 acute coronary syndrome trials,3,4 in a recent stroke trial,5 and in other ...
A Clinical Trial of Estrogen-Replacement Therapy After Ischemic Stroke. - CM Viscoli, LM Brass, WN Kernan, PM Sarrel, S … - Obstetrical & Gynecological Survey, 2002 - obgynsurvey.com ... A Clinical Trial of Estrogen-Replacement Therapy After IschemicStroke. ... A Clinical Trial of Estrogen-Replacement Therapy After IschemicStroke. ...
Intra-arterial Prourokinase for Acute Ischemic Stroke - A Furlan, R Higashida, L Wechsler, M Gent, H … - stroke, 1999 - utsouthwestern.edu ... large, randomized clini- cal trial. 9 Intra-arterial (IA) thromboly- sis lends itself
to such a design in se- lected patients with acute ischemicstroke. ...
[CITATION] … in Patients With Ischemic Stroke to Prevent Recurrent Stroke, Myocardial Infarction, and Death: The … - JF Toole, MR Malinow, LE Chambless, JD Spence, LC … - JAMA: The Journal of the American Medical Association, 2004 - JAMA ... Nondisabling ischemicstroke(Modified Rankin Stroke Scale 3 ... obscure evaluation of
recurrent stroke Life expectancy <2 ... Participation in another trial with active ...
Acute ischemic stroke, patient enrollment permanently discontinued in phase 3 trial of ReoPro
Patient enrollment in the phase 3 trial of ReoPro ( Abciximab ) for the treatment of acute ischemic stroke has been permanently discontinued.
Based on careful review of the data and the observed benefit-risk profile, the trial's independent Safety and Efficacy Monitoring Committee ( SEMC ) for the Abciximab in Emergent Stroke Treatment Trial-II ( AbESTT-II ) recommended that the study not resume enrollment.
After reviewing these recommendations, the principal investigators, the AbESTT-II Executive Committee and Companies, Centocor and Lilly, have unanimously agreed with the SEMC, and, effective immediately, permanently discontinued enrollment in the trial.
On October 4, 2005, Centocor and Lilly announced that enrollment in AbESTT-II had been temporarily suspended following a recommendation from the SEMC based on an observed safety concern in the data that it had reviewed.
ReoPro is approved in the United States and many other countries around the world as an adjunct to percutaneous coronary intervention ( PCI ) for the prevention of cardiac ischemic complications in patients undergoing PCI and in patients with unstable angina not responding to conventional medical therapy when PCI is planned within 24 hours. The companies clearly reiterated that they are not aware of any new data that change the favorable product profile of ReoPro in approved indications - indications that are supported by more than 14 randomized clinical trials and a decade of clinical experience.
ReoPro is not indicated in patients having an acute ischemic stroke.
AbESTT-II was a Phase 3, multinational, multicenter, randomized, double-blind placebo-controlled study evaluating the safety and efficacy of ReoPro in improving neurological function and minimizing disability in patients who have had an acute ischemic stroke.
Preliminary results from other trials suggested that ReoPro might have been useful in the treatment of stroke beyond the three-hour time window in which the only currently approved therapy is used to dissolve blood clots in ischemic stroke patients.
Most stroke patients do not arrive in the emergency department within three hours of symptom onset.
The trial evaluated two populations: patients randomized within 4.5 hours with planned treatment within five hours of stroke onset ( primary analysis population, n=1200 ) and a companion population of patients randomized 4.5-5.5 hours after stroke onset with planned treatment within six hours or who awaken with stroke symptoms and can be randomized within 2.5 hours of awakening ( n=600 ).
In May 2005, treatment of the small segment of patients awakening after having suffered a stroke was stopped because of an increased risk of intracranial hemorrhage in that population.
At that time, the SEMC recommended continuing enrollment with the remaining groups being evaluated in the trial.
Approximately 150 clinical trial sites participated in the AbESTT-II worldwide trial, which began in 2003. The goal for enrollment was 1,800 participants.
